Trial Profile
A Phase II Trial of Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Cyclophosphamide; Topotecan
- Indications Ewing's sarcoma; Neuroblastoma
- Focus Therapeutic Use
- 31 Oct 2018 Status changed from active, no longer recruiting to completed.
- 17 Apr 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 17 Apr 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.